Bone loss over time and risk of osteoporosis in advanced pancreatic cancer
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Tsuyoshi Takeda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Pancreatic Neoplasms, Bone Density. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
Pancreatic cancer has a high risk of developing osteoporosis. However, the impact of osteoporosis has not been well-studied. This study aimed to evaluate bone loss over time and risk of osteoporosis in patients with advanced pancreatic cancer.
Methods
We retrospectively examined consecutive patients with unresectable pancreatic cancer who had evaluable computed tomography before treatment and at 1-year follow-up. Bone mineral density at the first lumbar vertebra was measured on computed tomography, and osteoporosis was defined as bone mineral density < 135 Hounsfield units. The prevalence and risk factors for osteoporosis, changes in bone mineral density over time and incidence of bone fractures were analyzed.
Results
Three hundred eighty patients were included. Osteoporosis was associated with older age, female sex, low body mass index and poor performance status at baseline. A consistent decrease in bone mineral density was observed over time regardless of age, sex or disease status, resulting in an increase in the prevalence of osteoporosis over time (47% at baseline, 79% at 1 year, 88% at 2 years, 89% at 3 years, 95% at 4 years and 100% at 5 years). Changes in bone mineral density from baseline were greater in patients with locally-advanced pancreatic cancer, in those who received modified FOLFIRINOX or S-IROX for more than 3 months, and in those who received radiation therapy. Incident fractures developed in 45 patients (12%) during follow-up.
Conclusions
Osteoporosis and osteoporotic fractures were highly prevalent in patients with advanced pancreatic cancer. This study highlights the importance of screening for osteoporosis in such patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Tsuyoshi Takeda, Takaaki Furukawa, Takafumi Mie
Zitieren
APA
Takeda, T., Sasaki, T., Okamoto, T., Hirai, T., Ishitsuka, T., Yamada, M., Nakagawa, H., Furukawa, T., Mie, T., Kasuga, A., Ozaka, M., & Sasahira, N. (2024). Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae028
Vancouver
Takeda T, Sasaki T, Okamoto T, Hirai T, Ishitsuka T, Yamada M, et al. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae028
BibTeX
@article{Takeda2024,
author = {Takeda, Tsuyoshi and Sasaki, Takashi and Okamoto, Takeshi and Hirai, Tatsuki and Ishitsuka, Takahiro and Yamada, Manabu and Nakagawa, Hiroki and Furukawa, Takaaki and Mie, Takafumi and Kasuga, Akiyoshi and Ozaka, Masato and Sasahira, Naoki},
title = {Bone loss over time and risk of osteoporosis in advanced pancreatic cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae028}
}
EUVIMED